Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
September 10, 2024 07:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences
September 04, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
August 13, 2024 07:00 ET
|
Jasper Therapeutics, Inc.
Enrollment in BEACON and SPOTLIGHT studies progressing faster than expected; enrollment in the 240mg single-dose cohort of the BEACON study ongoing Additional dosing cohort (180mg Q8W) added to...
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
June 19, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
June 17, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
June 14, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
May 30, 2024 18:05 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
May 14, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
May 13, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in...